Stock Analysis, Dividends, Split History
HCOM / Hawaiian Telcom Holdco, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.
|Market Cap ($M)||337.42|
|Enterprise Value ($M)||633.53|
|Book Value ($M)||218.30|
|Book Value / Share||18.71|
|Price / Book||1.55|
|NCAV / Share||-37.55|
|Price / NCAV||-0.77|
|Identifiers and Descriptors|
|Central Index Key (CIK)||1487986|
|SIC 4899 - Communications Services, Not Elsewhere Classified|
Stock splits are used by Hawaiian Telcom Holdco, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.
23h - Asif
Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...
23h - Asif
Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...
2018-08-20 - Asif
General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...
Related News Stories
Cincinnati Bell Inc. (CBB - Free Report) reported disappointing results in the second quarter of 2018, wherein both the top line and the bottom line missed the Zacks Consensus Estimate.
In the last five trading days, telecom stocks witnessed a sharp rise initially as China eased some foreign investment curbs but fell slightly thereafter to maintain a flat trajectory. The stocks regained the lost ground later in the week due to temporary relief to ZTE to resume some business activities. Amid the looming trade war tensions between the United States and China, the communist nation took a positive step toward easing the limits on foreign ownership in some of its closely guarded sectors. (6-0)
Cincinnati Bell Inc. (CBB - Free Report) recently announced that it has completed the acquisition of Hawaiian Telcom Holdco, Inc. . The financial terms of the deal remained undisclosed. Headquartered in Honolulu, Hawaiian Telcom is Hawai‘i’s fiber-centric technology leader and provides integrated communications, broadband, data center and entertainment solutions for business and residential customers. (2-0)
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. As usual, a new quarter and the second half of the trading year will begin with a shortened week due to the Independence Day holiday -- a "trading week interruptus," with July 4 landing on Wednesday. (254-5)
In the last five trading days, telecom stocks flattered to deceive as the initial upturn was replaced by a persistent downturn for the most part of the past week as President Trump renewed fears of a fresh trade war with China. The on-again off-again trade war between the United States and China took a new turn when Trump imposed a fresh salvo of tariffs worth $50 billion on Chinese imports last week. (43-0)
Silicon Investor Message Boards
This table lists all message boards related to HCOM / Hawaiian Telcom Holdco, Inc. on message board site Silicon Investor.
|HCOM - HomeCom Communications u003c Short Term Gain? u003e||HCOM - HomeCom Communications u003c Short Term Gain? u003e||HCOM - HomeCom Communications u003c Short Term Gain? u003e|
as of ET